Breaking News Instant updates and real-time market news.

ONTX

Onconova

$2.35

0.05 (2.17%)

07:39
08/12/19
08/12
07:39
08/12/19
07:39

Onconova, Mission Bio partner for precision oncology clinical trials

Onconova Therapeutics and Mission Bio announced that they have formed a collaboration to utilize the Mission Bio Tapestri Platform for targeted single-cell DNA analysis to study Onconova's novel cancer therapy, rigosertib, through clinical trials. With the Mission Bio Tapestri Platform, researchers can detect rare cancer subclones and co-occurring cancer mutations at the single-cell level, offering a precise way to measure therapy response and disease progression. Supporting the pharma and biopharma industries through clinical trials and commercialization continues to be a focus for Mission Bio. Ras proteins control cell proliferation, and mutation of this protein can lead to cancer in affected individuals. Ras is mutated in over 30 percent of patients with cancer, making it one of the most sought-after targets. Onconova is developing rigosertib, a first-in-class, small molecule Ras mimetic, to target this mutation. Rigosertib blocks the activation of Ras effector proteins, thus modulating the Ras pathway. Onconova's goal is to fully enroll INSPIRE, its phase 3 clinical trial studying rigosertib in higher-risk MDS patients who fail the current standard of care, by year-end.

  • 14

    Aug

ONTX Onconova
$2.35

0.05 (2.17%)

10/11/18
MAXM
10/11/18
NO CHANGE
Target $16
MAXM
Buy
Onconova price target lowered to $16 at Maxim to reflect reverse stock split
Maxim analyst Jason MacCarthy lowered his price target on Onconova to $16 from $45 to reflect the impact of the company's 1-for-15 reverse stock split announced on September 25th which reduced the number of shares outstanding to 5.67M from 85.11M. McCarthy also keeps his Buy rating on the shares and notes that his bullish stance remains intact as the company's "rigosertib phase 3 program continues to enroll and timelines remain unchanged".
12/03/18
12/03/18
NO CHANGE

Onconova presents rigosertib with azacitidine data at ASH
Onconova Therapeutics announced the presentation of the efficacy and safety results of oral rigosertib in combination with azacitidine in patients with HR-MDS reported at an oral presentation during the American Society of Hematology, or ASH. Rigosertib, the company's lead compound, is being evaluated in both intravenous and oral forms. Seventy-four patients were treated with a median age of 69 years at nine clinical sites and received either 840 mg or 1,120 mg of oral rigosertib daily divided into two doses, in combination with a standard dose of injectable azacitidine. Of the 55 evaluable patients, 29 patients were treated with a daily dose of 1,120 mg of oral rigosertib, either 560 mg twice daily or 840 mg in the a.m. and 280 mg in the afternoon. Twenty-six patients were treated with 560 mg in the AM and 280 mg in the PM for the first three weeks of a four-week cycle. All patients also received 75 mg/m2/day SC or IV azacitidine during the second week of the four-week cycle. The median duration of treatment for the HMA naive and HMA failed patients was 7.8 and 4.9 months respectively. The median duration of response in these groups was 12.2 and 10.8 months, respectively. The overall response rate, or ORR, using the IWG 2006 criteria, in 29 HMA naive patients was 90%, including 10 patients with complete remission, or CR. Among the 26 evaluable HMA-failed patients the ORR was 54% including 8% CR or PR. The median time to initial and best response were 1 and 4 cycles in the HMA naive group and 2 and 5 cycles in the HMA failed group. The safety population received at least 1 dose of oral rigosertib. The combination was well tolerated. Other than genitourinary adverse events, or AEs, the AE profile was similar to those described for azacitidine alone in this patient population. Genitourinary AEs, including hematuria and dysuria were observed. A safety optimization strategy was implemented for the higher dose cohort of 1,120 mg of oral rigosertib. These strategies included earlier in the day administration of the PM dose, oral hydration, monitoring of urinary pH and mandatory bladder emptying at night. Collectively these strategies resulted in mitigation of the target genitourinary AEs, including reduction of genitourinary grade 3 AEs reported from an earlier cohort despite receiving a higher dose of oral rigosertib. In conclusion, oral rigosertib in combination with azacitidine was well tolerated in HMA naive and HMA failed HR-MDS patients. The combination produced an encouraging rate of overall response and complete remission in both groups. The safety optimization strategies and increased dose exploration of oral rigosertib in the combination is leading to the development of a pivotal Phase 3 trial in HMA and chemotherapy naive patients. Onconova plans to meet with the FDA to discuss the results of the Phase 2 trial and the planned Phase 3 trial, and to seek a special protocol assessment. The company has partnered rigosertib with SymBio Pharmaceuticals, for Japan and Korea, and with Pint Pharma for Latin American countries. Both partners have indicated their interest in participating in the proposed new pivotal Phase 3 trial by enrolling patients in their respective territories. SymBio is currently conducting Phase 1 studies with oral rigosertib in Japan and also participating in the Phase 3 global INSPIRE trial. The company is also actively seeking additional collaborations for rigosertib in other geographies.
07/25/19
NBLE
07/25/19
INITIATION
Target $12
NBLE
Outperform
Onconova initiated with an Outperform at Noble Capital
Noble Capital analyst Ahu Demir initiated Onconova with an Outperform rating and $12 price target, noting that the company's Phase 3 INSPIRE study of rigosertib in patients with high-risk myelodysplastic syndrome is expected to have a data readout in 2020. While the company's main focus is MDS, Demir sees it having promising early stage opportunities beyond MDS, he noted. He believes the current stock price does not reflect the potential of Onconova's pipeline, Demir added.
07/25/19
07/25/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. FleetCor (FLT) initiated with a Neutral at Baird. 2. Medifast (MED) initiated with a Buy at Jefferies. 3. EnLink Midstream (ENLC) initiated with a Neutral at Mizuho. 4. Onconova (ONTX) initiated with an Outperform at Noble Capital. 5. Gold Standard Ventures (GSV) initiated with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

URBN

Urban Outfitters

$20.98

0.12 (0.58%)

16:09
08/20/19
08/20
16:09
08/20/19
16:09
Hot Stocks
Breaking Hot Stocks news story on Urban Outfitters »

Urban Outfitters down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 22

    Aug

  • 25

    Sep

SCSC

Scansource

$31.55

-0.24 (-0.75%)

16:09
08/20/19
08/20
16:09
08/20/19
16:09
Earnings
Scansource sees Q1 non-GAAP EPS 70c-75c, consensus 35c »

Sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 19

    Sep

URBN

Urban Outfitters

$20.97

0.11 (0.53%)

16:09
08/20/19
08/20
16:09
08/20/19
16:09
Hot Stocks
Urban Outfitters says total inventory increased by $64.4M as of July 31 »

As of July 31, total…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 22

    Aug

  • 25

    Sep

URBN

Urban Outfitters

$20.96

0.1 (0.48%)

16:08
08/20/19
08/20
16:08
08/20/19
16:08
Hot Stocks
Urban Outfitters reports Q2 comparable retail segment net sales down 3% »

Q2 comparable retail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 22

    Aug

  • 25

    Sep

URBN

Urban Outfitters

$20.92

0.06 (0.29%)

16:07
08/20/19
08/20
16:07
08/20/19
16:07
Earnings
Urban Outfitters reports Q2 EPS 61c, consensus 58c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 22

    Aug

  • 25

    Sep

SCSC

Scansource

$31.85

0.06 (0.19%)

16:06
08/20/19
08/20
16:06
08/20/19
16:06
Earnings
Scansource reports Q4 non-GAAP EPS 71c, consensus 43c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 19

    Sep

REI

Ring Energy

$1.66

-0.07 (-4.06%)

16:06
08/20/19
08/20
16:06
08/20/19
16:06
Earnings
Ring Energy releases mid-Q3 operations update »

Ring Energy released a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYBX

Synlogic

$3.45

-1.37 (-28.42%)

16:06
08/20/19
08/20
16:06
08/20/19
16:06
Downgrade
Synlogic rating change  »

Synlogic downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CREE

Cree

$58.36

0.08 (0.14%)

16:03
08/20/19
08/20
16:03
08/20/19
16:03
Earnings
Cree sees Q1 adjusted EPS (7c)-(3c), consensus 15c »

Sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

MOGO

Mogo Finance

$2.60

(0.00%)

16:03
08/20/19
08/20
16:03
08/20/19
16:03
Hot Stocks
Mogo Finance surpasses 900,000 member milestone »

Mogo announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CREE

Cree

$58.35

0.07 (0.12%)

16:01
08/20/19
08/20
16:01
08/20/19
16:01
Earnings
Cree reports Q4 adjusted EPS 11c, consensus 10c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

BCRX

BioCryst

$2.70

0.025 (0.94%)

16:00
08/20/19
08/20
16:00
08/20/19
16:00
Conference/Events
BioCryst management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

15:55
08/20/19
08/20
15:55
08/20/19
15:55
Conference/Events
Cantor Fitzgerald tech analyst to hold an analyst/industry conference call »

Technology & Business…

LZB

La-Z-Boy

$30.73

-1.14 (-3.58%)

15:42
08/20/19
08/20
15:42
08/20/19
15:42
Options
La Z Boy options imply 11.9% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 27

    Aug

MAS

Masco

$39.07

0.26 (0.67%)

15:41
08/20/19
08/20
15:41
08/20/19
15:41
Periodicals
Bain, AIP said bidding on Masco cabinet unit, Bloomberg reports »

The unit is said to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALC

Alcon

$62.41

0.62 (1.00%)

15:34
08/20/19
08/20
15:34
08/20/19
15:34
Options
Alcon options imply 5.4% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 04

    Sep

  • 09

    Sep

TSLA

Tesla

$225.57

-1.18 (-0.52%)

, WMT

Walmart

$112.40

-1.36 (-1.20%)

15:28
08/20/19
08/20
15:28
08/20/19
15:28
Periodicals
Breaking Periodicals news story on Tesla, Walmart »

Walmart sues Tesla over…

TSLA

Tesla

$225.57

-1.18 (-0.52%)

WMT

Walmart

$112.40

-1.36 (-1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 15

    Sep

  • 23

    Sep

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

VTGN

VistaGen Therapeutics

$0.62

(0.00%)

15:26
08/20/19
08/20
15:26
08/20/19
15:26
Hot Stocks
VistaGen not 'a one product' company, says CEO »

VistaGen Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

JKHY

Jack Henry

$140.60

-0.91 (-0.64%)

15:19
08/20/19
08/20
15:19
08/20/19
15:19
Options
Jack Henry options imply 5.9% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 11

    Sep

  • 12

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
08/20/19
08/20
15:17
08/20/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
08/20/19
08/20
15:16
08/20/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VTGN

VistaGen Therapeutics

$0.62

(0.00%)

15:11
08/20/19
08/20
15:11
08/20/19
15:11
Hot Stocks
VistaGen's Singh says partnerships in large markets outside U.S. make most sense »

VistaGen Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

SABR

Sabre

$23.74

-0.19 (-0.79%)

15:10
08/20/19
08/20
15:10
08/20/19
15:10
Hot Stocks
Sabre to challenge DOJ lawsuit seeking to block Farelogix acquisition »

Sabre Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTE

PolarityTE

$5.05

-0.14 (-2.70%)

15:09
08/20/19
08/20
15:09
08/20/19
15:09
Recommendations
PolarityTE analyst commentary at Cantor Fitzgerald »

PolarityTE's patent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 21

    Aug

  • 09

    Sep

STRL

Sterling Construction

$11.55

0.31 (2.76%)

15:06
08/20/19
08/20
15:06
08/20/19
15:06
Conference/Events
Sterling Construction management to meet with KeyBanc »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.